Snake Venom Components: Tools and Cures to Target Cardiovascular Diseases
Cardiovascular diseases (CVDs) are considered as a major cause of death worldwide. Therefore, identifying and developing therapeutic strategies to treat and reduce the prevalence of CVDs is a major medical challenge. Several drugs used for the treatment of CVDs, such as captopril, emerged from natur...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-04-01
|
| Series: | Molecules |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1420-3049/26/8/2223 |
| _version_ | 1797537957105631232 |
|---|---|
| author | Jacinthe Frangieh Mohamad Rima Ziad Fajloun Daniel Henrion Jean-Marc Sabatier Christian Legros César Mattei |
| author_facet | Jacinthe Frangieh Mohamad Rima Ziad Fajloun Daniel Henrion Jean-Marc Sabatier Christian Legros César Mattei |
| author_sort | Jacinthe Frangieh |
| collection | DOAJ |
| description | Cardiovascular diseases (CVDs) are considered as a major cause of death worldwide. Therefore, identifying and developing therapeutic strategies to treat and reduce the prevalence of CVDs is a major medical challenge. Several drugs used for the treatment of CVDs, such as captopril, emerged from natural products, namely snake venoms. These venoms are complex mixtures of bioactive molecules, which, among other physiological networks, target the cardiovascular system, leading to them being considered in the development and design of new drugs. In this review, we describe some snake venom molecules targeting the cardiovascular system such as phospholipase A2 (PLA2), natriuretic peptides (NPs), bradykinin-potentiating peptides (BPPs), cysteine-rich secretory proteins (CRISPs), disintegrins, fibrinolytic enzymes, and three-finger toxins (3FTXs). In addition, their molecular targets, and mechanisms of action—vasorelaxation, inhibition of platelet aggregation, cardioprotective activities—are discussed. The dissection of their biological effects at the molecular scale give insights for the development of future snake venom-derived drugs. |
| first_indexed | 2024-03-10T12:24:34Z |
| format | Article |
| id | doaj.art-e0ead1770f424e3bbf4ebd99edeab135 |
| institution | Directory Open Access Journal |
| issn | 1420-3049 |
| language | English |
| last_indexed | 2024-03-10T12:24:34Z |
| publishDate | 2021-04-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Molecules |
| spelling | doaj.art-e0ead1770f424e3bbf4ebd99edeab1352023-11-21T15:14:16ZengMDPI AGMolecules1420-30492021-04-01268222310.3390/molecules26082223Snake Venom Components: Tools and Cures to Target Cardiovascular DiseasesJacinthe Frangieh0Mohamad Rima1Ziad Fajloun2Daniel Henrion3Jean-Marc Sabatier4Christian Legros5César Mattei6Laboratory of Applied Biotechnology (LBA3B), Azm Center for Research in Biotechnology and Its Applications, EDST, Lebanese University, Tripoli 1300, LebanonInstitut de Génétique et de Biologie Moléculaire et Cellulaire (IGBMC), INSERM, CNRS, Université de Strasbourg, 67400 Illkirch, FranceLaboratory of Applied Biotechnology (LBA3B), Azm Center for Research in Biotechnology and Its Applications, EDST, Lebanese University, Tripoli 1300, LebanonUniversity Angers, INSERM U1083, CNRS UMR6015, MITOVASC, Team 2 CarMe, SFR ICAT, 49000 Angers, FranceFaculté de Médecine Secteur Nord, 51, Institut de Neuro-Physiopathologie, Université Aix-Marseille, UMR 7051, Boulevard Pierre Dramard-CS80011, CEDEX 15, 13344 Marseille, FranceUniversity Angers, INSERM U1083, CNRS UMR6015, MITOVASC, Team 2 CarMe, SFR ICAT, 49000 Angers, FranceUniversity Angers, INSERM U1083, CNRS UMR6015, MITOVASC, Team 2 CarMe, SFR ICAT, 49000 Angers, FranceCardiovascular diseases (CVDs) are considered as a major cause of death worldwide. Therefore, identifying and developing therapeutic strategies to treat and reduce the prevalence of CVDs is a major medical challenge. Several drugs used for the treatment of CVDs, such as captopril, emerged from natural products, namely snake venoms. These venoms are complex mixtures of bioactive molecules, which, among other physiological networks, target the cardiovascular system, leading to them being considered in the development and design of new drugs. In this review, we describe some snake venom molecules targeting the cardiovascular system such as phospholipase A2 (PLA2), natriuretic peptides (NPs), bradykinin-potentiating peptides (BPPs), cysteine-rich secretory proteins (CRISPs), disintegrins, fibrinolytic enzymes, and three-finger toxins (3FTXs). In addition, their molecular targets, and mechanisms of action—vasorelaxation, inhibition of platelet aggregation, cardioprotective activities—are discussed. The dissection of their biological effects at the molecular scale give insights for the development of future snake venom-derived drugs.https://www.mdpi.com/1420-3049/26/8/2223snake venomcardiovascular diseaseshypotensive agentanti-platelet agentvasorelaxant effectdrugs discovery |
| spellingShingle | Jacinthe Frangieh Mohamad Rima Ziad Fajloun Daniel Henrion Jean-Marc Sabatier Christian Legros César Mattei Snake Venom Components: Tools and Cures to Target Cardiovascular Diseases Molecules snake venom cardiovascular diseases hypotensive agent anti-platelet agent vasorelaxant effect drugs discovery |
| title | Snake Venom Components: Tools and Cures to Target Cardiovascular Diseases |
| title_full | Snake Venom Components: Tools and Cures to Target Cardiovascular Diseases |
| title_fullStr | Snake Venom Components: Tools and Cures to Target Cardiovascular Diseases |
| title_full_unstemmed | Snake Venom Components: Tools and Cures to Target Cardiovascular Diseases |
| title_short | Snake Venom Components: Tools and Cures to Target Cardiovascular Diseases |
| title_sort | snake venom components tools and cures to target cardiovascular diseases |
| topic | snake venom cardiovascular diseases hypotensive agent anti-platelet agent vasorelaxant effect drugs discovery |
| url | https://www.mdpi.com/1420-3049/26/8/2223 |
| work_keys_str_mv | AT jacinthefrangieh snakevenomcomponentstoolsandcurestotargetcardiovasculardiseases AT mohamadrima snakevenomcomponentstoolsandcurestotargetcardiovasculardiseases AT ziadfajloun snakevenomcomponentstoolsandcurestotargetcardiovasculardiseases AT danielhenrion snakevenomcomponentstoolsandcurestotargetcardiovasculardiseases AT jeanmarcsabatier snakevenomcomponentstoolsandcurestotargetcardiovasculardiseases AT christianlegros snakevenomcomponentstoolsandcurestotargetcardiovasculardiseases AT cesarmattei snakevenomcomponentstoolsandcurestotargetcardiovasculardiseases |